Complete Response With Fotemustine and Bevacizumab After Early Progression Following Radiotherapy and Temozolomide Treatment in Patient With Glioblastoma Multiforme

Journal of Cancer Metastasis and Treatment
doi 10.4103/2394-4722.153446
Full Text
Abstract

Available in full text

Date
Authors
Publisher

OAE Publishing Inc.

Related search

Cost-Effectiveness Analysis of Bevacizumab, Fotemustine and Extended-Dose Temozolomide in Patients With Recurrent Glioblastoma in Spain

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2014English

Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2011English

Glioblastoma Multiforme in a Patient With Isolated Hemimegalencephaly

Journal of Neurological Surgery Reports
2015English

Acute Lymphoblastic Leukemia Following Temozolomide Treatment in a Patient With Glioblastoma: A Case Report and Review of the Literature

Oncology Letters
Cancer ResearchOncology
2018English

Update and Developments in the Treatment of Glioblastoma Multiforme &Ndash; Focus on Bevacizumab

Pharmacogenomics and Personalized Medicine
Molecular MedicinePharmacology
2010English

Phase II Trial of Temozolomide (TMZ) Plus Irinotecan (CPT-11) in Adults With Newly Diagnosed Glioblastoma Multiforme Before Radiotherapy

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2009English

Evaluation of Early Imaging Response Criteria in Glioblastoma Multiforme

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2011English

Comparative Effectiveness of Radiotherapy With vs. Without Temozolomide in Older Patients With Glioblastoma

Journal of Neuro-Oncology
Cancer ResearchOncologyNeurology
2016English

Response to Ranibizumab Following Tachyphylaxis to Bevacizumab in a Patient With Radiation Maculopathy Following Stereotactic Fractionated Radiotherapy for Optic Nerve Meningioma

Archives of Ophthalmology
2012English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy